Non-alcoholic fatty liver disease and diabetes

by Hazlehurst, Jonathan M., Woods, Conor, Marjot, Thomas, Cobbold, Jeremy F., Tomlinson, Jeremy W.
Published 2016

SFRP2 Is Associated with Increased Adiposity and VEGF Expression

by Crowley, Rachel K., O’Reilly, Michael W., Bujalska, Iwona J., Hassan-Smith, Zaki K., Hazlehurst, Jonathan M., Foucault, Danielle R., Stewart, Paul M., Tomlinson, Jeremy W.
Published 2016

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

by Armstrong, Matthew J., Hull, Diana, Guo, Kathy, Barton, Darren, Hazlehurst, Jonathan M., Gathercole, Laura L., Nasiri, Maryam, Yu, Jinglei, Gough, Stephen C., Newsome, Philip N., Tomlinson, Jeremy W.
Published 2016

Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man

by Hazlehurst, Jonathan M., Oprescu, Andrei I., Nikolaou, Nikolaos, Di Guida, Riccardo, Grinbergs, Annabel E. K., Davies, Nigel P., Flintham, Robert B., Armstrong, Matthew J., Taylor, Angela E., Hughes, Beverly A., Yu, Jinglei, Hodson, Leanne, Dunn, Warwick B., Tomlinson, Jeremy W.
Published 2016

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

by Armstrong, Matthew James, Gaunt, Piers, Aithal, Guruprasad P., Barton, Darren, Hull, Diana, Parker, Richard, Hazlehurst, Jonathan M., Guo, Kathy, Abouda, George, Aldersley, Mark A., Stocken, Deborah, Gough, Stephen C., Tomlinson, Jeremy W., Brown, Rachel M., Hübscher, Stefan G., Newsome, Philip N.
Published 2015